Encouraging Phase 3 Results: Marstacimab for Hemophilia A or B with Inhibitors
Heme Today shared a thrilled post on LinkedIn:
”ICYMI in hemophilia reporting on Heme Today: Marstacimab from Pfizer performed impressively in a phase 3 study as tx for hemophilia A or B with inhibitors.”
To learn more, follow the link.
A phase 3 study has yielded favorable topline results for Marstacimab (HYMPAVZI), showing promising efficacy and safety in treating severe hemophilia A or B with inhibitors.
Pfizer announced the positive findings, highlighting the therapy’s potential to address an important unmet need for patients with antibodies that limit factor-based prophylaxis.
“These encouraging results demonstrate HYMPAVZI’s potential to help people living with hemophilia A or B with inhibitors, meeting an important need for patients with antibodies that neutralize most factor-based prophylactic options used to manage bleeding episodes,” commented Pfizer’s chief inflammation & immunology officer Michael Vincent, MD, PhD.
Stay updated on the latest scientific advancements in the field of hemophilia management with Hemostasis Today.
-
Jul 18, 2025, 12:18NBCA Hosts PEP Talk with Dr. Parks on Aging and Blood Clots
-
Jul 18, 2025, 12:14WFH Shares Powerful Patient Story on Access to Bleeding Disorders Treatment
-
Jul 18, 2025, 11:53HTRS Shines Spotlight on Faculty Powering the Future of Hemostasis and Thrombosis
-
Jul 16, 2025, 17:23ISTH 2025 Spotlight: HOPE-B Trial Highlights Sustained Efficacy of Gene Therapy for Hemophilia B
-
Jul 16, 2025, 15:00Together with Dr. Bethany Samuelson Bannow – Let’s Keep Hematology Moving Forward
-
Jul 19, 2025, 17:16Promising 85% Response: Ru-D Regimen Shows Hope for Adults with HLH
-
Jul 19, 2025, 16:16A Potential Link to Recurrent Pregnancy Loss: Monoclonal Anti-PF4 Antibodies' Role
-
Jul 19, 2025, 15:2115% Recanalization Rate During Transfer in Basilar Artery Occlusion: A Missed Opportunity?
-
Jul 18, 2025, 18:54New Issue Alert! Advances in Stroke: Vascular and Interventional Neurology 2025
-
Jul 16, 2025, 11:06Why Pain Feels Different for Everyone - The Guardian
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 13, 2025, 15:35World’s First Liver Transplant for Plasminogen Deficiency Performed at KFSHRC
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 16, 2025, 10:24Salma Ismail: Honored to Be Invited By the EHA2025 as Part of Their Lighting the Flame Program
-
Jul 15, 2025, 17:002022 Chemistry Laureate Carolyn Bertozzi Shares Inspiring Advice for Young Scientists
-
Jul 15, 2025, 16:42A 200+ Year Historical Review of Women and Hemophilia: Shifting Perspectives
-
Jul 10, 2025, 18:25Dr. Carol Kasper: Honoring the Legacy
-
Jul 8, 2025, 08:26ASH and HVO Collaborate to Expand Hematology Training in LMICs